Crossref
For adults with high-risk smoldering multiple myeloma (SMM), how does early intervention with monoclonal antibody therapy (daratumumab) compare with active monitoring?
Cochrane Clinical Answers · 29.06.2026
DOI: 10.1002/cca.4793 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cochrane Clinical Answers, online erschienen am 29.06.2026. Verfasst von Sera Tort. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Tort, S. (2026). For adults with high-risk smoldering multiple myeloma (SMM), how does early intervention with monoclonal antibody therapy (daratumumab) compare with active monitoring?. Cochrane Clinical Answers. https://doi.org/10.1002/cca.4793
Vancouver
Tort S. For adults with high-risk smoldering multiple myeloma (SMM), how does early intervention with monoclonal antibody therapy (daratumumab) compare with active monitoring?. Cochrane Clinical Answers. 2026. doi:10.1002/cca.4793
BibTeX
@article{Tort2026,
author = {Tort, Sera},
title = {For adults with high-risk smoldering multiple myeloma (SMM), how does early intervention with monoclonal antibody therapy (daratumumab) compare with active monitoring?},
journal = {Cochrane Clinical Answers},
year = {2026},
doi = {10.1002/cca.4793}
}
EUVIMED